Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110683 | 1.00 | CHRM3 (0.67) | CHRM3ROCK2CYP3A4CYP2D6CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL4048489 | 0.94 | CHRM3 (0.60) | CHRM3ROCK2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4103849 | 0.91 | CHRM3 (0.69) | CHRM3ROCK2 | |
| SCHEMBL4103847 | 0.91 | CHRM3 (0.69) | CHRM3ROCK2 | |
| SCHEMBL4105070 | 0.87 | CHRM3 (0.70) | CHRM3ROCK2ROCK1 | |
| SCHEMBL4105076 | 0.87 | CHRM3 (0.70) | CHRM3ROCK2ROCK1 | |
| SCHEMBL4099884 | 0.87 | CHRM3 (0.72) | CHRM3 | |
| SCHEMBL4099893 | 0.87 | CHRM3 (0.72) | CHRM3 | |
| Trifluoroacetic Acid SCHEMBL4054104 | 0.86 | CHRM3 (0.62) | CHRM3ROCK2 | |
| SCHEMBL12725362 | 0.85 | CHRM3 (0.72) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | CHRM3 1/4885ROCK2 3635/4885CYP3A4 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.